I do not wait.

A credible, previously unlabeled risk of liver failure in a chronic-pain drug is a patient-safety crisis, a regulatory crisis, and a securities-disclosure issue at the same time. Waiting for “more data” is the worst of all worlds: more patients get hurt, regulators lose trust, plaintiffs get punitive-damages evidence, and the earnings call becomes a potential misstatement.

Rough math: 4,000,000 patients × (1 / 8,000 over 5 years) ≈ 500 liver-failure cases over 5 years, or about 100/year if risk is roughly spread over time — nearly 2 cases/week. A 6‑month delay could mean dozens of serious injuries while we sit on the information.

First principles

In the next 48 hours, my priorities are:

1. Reduce patient harm immediately
2. Notify regulators immediately
3. Prepare truthful public disclosure before the earnings call
4. Stop promotion and new patient growth
5. Preserve legal defensibility through transparency, documentation, and speed
6. Keep employees aligned and prevent insider-trading/comms mistakes

---

Hour-by-hour plan: next 48 hours

Hours 0–23

Hour	Action	Why
0	Activate crisis command center: CEO, CMO, GC, Head of Pharmacovigilance, Regulatory Affairs, CFO, COO/Quality, Comms, HR. Immediate stop on all promotion for the drug: DTC ads, sales detailing, samples, speaker programs, digital campaigns. Immediate insider-trading blackout for directors/executives and halt buybacks.	Promotion cannot continue while we have a credible unlabeled life-threatening risk. Trading blackout is mandatory because this is clearly material nonpublic information.
1	Get the research team in a room. Review the exact signal: data source, methods, confidence intervals, causality strength, number of observed/estimated cases, patient subgroups, time-to-onset, reversibility.	I need the sharpest possible understanding before speaking to regulators and the board.
2	Lock the data and issue a litigation/document hold across safety, clinical, medical, commercial, and quality teams. Preserve emails, drafts, safety databases, manufacturing records, PV case notes.	Prevents spoliation risk and keeps the factual record clean.
3	Retain outside FDA/regulatory counsel, outside securities counsel, product-liability counsel, and a top-tier crisis communications firm.	Independent advice helps with speed, credibility, privilege, and making sure we don’t miss disclosure or reporting obligations.
4	Order an independent internal replication: biostats + pharmacoepidemiology re-run the analysis from raw data. In parallel, QA/CMC reviews recent lots, impurities, formulation changes, suppliers, complaints.	We need to confirm whether this is a molecule/class effect, a subgroup effect, or potentially a manufacturing/quality issue that could require a lot-specific recall.
5	Call the lead independent director/board chair and audit committee chair. Tell them this is an emergency and schedule a same-day board update call. Don’t wait 48 hours.	Governance starts now, not at the scheduled meeting.
6	Instruct Commercial and HR: no one is penalized for stopping promotion; suspend product-specific sales targets/incentives immediately.	If reps fear compensation loss, they will rationalize or improvise. Remove that pressure.
7	Notify the disclosure committee and CFO that this is likely material. Begin 8‑K/public disclosure prep.	Stock impact expected at 40% = obviously material. We cannot go into an earnings call pretending this doesn’t exist.
8	Regulatory Affairs requests urgent calls with FDA (and EMA/MHRA/PMDA/top markets if global). The message: serious newly identified safety signal, internal analysis underway, promotion already halted, urgent meeting requested within 24 hours.	Regulators hate surprises. Early notice buys trust.
9	Ask PV/Medical to produce a 2-page regulator/board fact sheet: incidence estimate, severity, likely exposed population, current labeling gap, known risk factors, proposed interim mitigation.	Everyone needs to work from one set of facts.
10	Pause new enrollment in any ongoing clinical trials involving the drug; notify investigators, DSMBs, and IRBs that a safety signal review is underway.	Trial participants deserve immediate protection; investigators must not learn from the press.
11	Medical Affairs drafts a Dear Healthcare Provider letter and patient guidance: symptoms of liver injury, who may be high-risk, recommended LFT monitoring, and “do not stop without speaking to your clinician.”	Patient safety action must be ready before public disclosure.
12	Hold the emergency board call. Present the facts, the rough expected harm if we delay, the legal/regulatory exposure, and my recommendation: notify regulators now, disclose publicly within ~24 hours, halt promotion, stop new starts, prepare a restricted-distribution or shipment-hold option.	Sets the tone: we are acting, not polling for courage.
13	CFO/Treasury starts financial stress testing: revenue loss scenarios, debt covenant headroom, liquidity needs, possible guidance withdrawal, manufacturing implications.	We need to survive the hit without appearing financially panicked.
14	Notify D&O and product-liability insurers.	Preserve coverage and avoid later denial for late notice.
15	Set up five workstreams with owners and 4-hour situation reports: (1) medical/regulatory, (2) legal/disclosure, (3) quality/supply, (4) communications/IR, (5) finance/HR.	Crisis execution fails without clear ownership.
16	Engage 2–3 external independent experts: hepatologist, pharmacoepidemiologist, drug safety expert.	External credibility matters with regulators, board, clinicians, and courts.
17	Conduct the first FDA head-up call. Share preliminary data, uncertainty, and the actions already taken. Ask specifically about urgent safety communication, label strengthening, and whether FDA prefers any wording changes.	Being open and action-oriented improves regulatory trust.
18	Put a temporary hold on all company-controlled outbound shipments, samples, starter kits, and new-patient support materials pending regulator input; preserve continuity planning for current patients.	Reduces new exposure quickly without forcing abrupt discontinuation for existing patients.
19	Begin preparing expedited safety reporting and a CBE-0 label supplement to strengthen warnings/precautions if supported by “newly acquired information.”	Full integrated reports may take months; urgent safety reporting and warning strengthening do not.
20	Draft the public disclosure package: press release, 8‑K, website banner, FAQs, hotline script, social response lines, employee manager notes.	Materiality + patient safety means disclosure needs to be coordinated and fast.
21	Limit internal knowledge to need-to-know leaders until public disclosure; remind them of blackout, confidentiality, and routing of all external inquiries.	Prevent leaks and Reg FD problems.
22	Design patient-support measures: free liver function testing, nurse line/case management, reimbursement for medically necessary transitions where possible.	If we say “patient safety first,” we must fund actual patient support immediately.
23	Review planned executive 10b5-1 trades, repurchases, M&A, and capital actions; suspend anything that would look opportunistic.	Optics matter, and regulators/plaintiffs will examine timing.

---

Hours 24–48

Hour	Action	Why
24	Submit initial formal safety notifications to FDA and major regulators; file/prepare the 8‑K and disclosure materials.	Creates the official record and starts the formal compliance clock.
25	Hold a deeper regulator call with CMO/Reg Affairs/outside counsel. Present proposed interim measures: no promotion, no new starts, strengthened warnings, HCP/patient communications, active surveillance.	Aligns company action with regulator expectations.
26	Finalize Dear HCP letter, patient FAQ, website copy, and call center scripts based on regulator feedback.	We want one message everywhere: doctors, patients, media, investors.
27	Publicly disclose the safety signal and immediate actions via press release + 8‑K. Message: serious preliminary safety signal; promotion halted; no new starts while review proceeds; patients should not stop abruptly without clinician guidance; symptoms to watch for; hotline/live support available.	This is the key moment. It protects patients, meets securities obligations, and avoids making the earnings call misleading.
28	Send the Dear HCP letter and notify pharmacies, wholesalers, PBMs, distributors, and trial investigators.	Prescribers and dispensing channels need direct operational guidance fast.
29	Turn on the 24/7 medical hotline and website portal; launch free/covered LFT support.	Patients and clinicians need somewhere to go immediately after the news breaks.
30	Send a company-wide communication and hold an all-hands/town hall for employees. Thank the research team, state clearly that there will be no retaliation, explain what we know/don’t know, and enforce a one-spokesperson policy.	Employee morale and integrity matter. People need facts and reassurance, not rumor.
31	Publicly announce earnings-call plan: default is keep the call on schedule, but state that we are withdrawing product-specific guidance (and broader guidance if necessary) until the impact is better understood.	Keeping the call signals control; withdrawing guidance avoids pretending to know what we don’t know.
32	Mandatory call with the sales force and customer-facing employees: they are not to promote, speculate, or answer off-script safety questions; all safety questions go to Medical Affairs.	Prevents inadvertent misstatements and off-label-like improvisation.
33	Start active case finding: re-query safety databases, literature, EHR/claims partners, foreign affiliates, and historical complaints for missed liver signals.	The signal may be larger, older, or subgroup-specific. We need better risk characterization immediately.
34	QA/CMC reports whether any lot/supplier/formulation pattern exists. If yes, prepare a targeted recall recommendation immediately.	If this is a quality issue rather than a pure pharmacology issue, the operational response changes fast.
35	Convene an Independent Safety Review Committee with external experts and internal medical leaders; document benefit-risk options: stronger warning/monitoring, REMS/restricted distribution, temporary suspension, or withdrawal.	Gives the board and regulators a structured, credible recommendation.
36	CEO + CMO conduct a brief media briefing. Tone: accountable, factual, patient-centered, no minimization, no defensiveness.	If we don’t frame the story, someone else will. The tone should reduce outrage, not inflame it.
37	Reach out to pain societies, hepatology groups, and patient advocacy organizations. Offer direct medical briefings.	Third-party clinical stakeholders help translate the message into practice and reduce confusion.
38	CFO finalizes downside scenarios: lost sales, inventory write-down risk, cash preservation steps, potential covenant issues.	We need to show the board and investors that the company can absorb the shock.
39	Suspend nonessential discretionary spending, repurchases, and optional capital uses; protect core R&D and patient-support funding.	Signals seriousness and preserves liquidity without looking reckless.
40	HR launches manager FAQ and employee support/EAP resources. Frontline employees may face hostile calls or moral distress.	This protects morale and keeps staff functioning.
41	Assemble the full board packet for the formal 48-hour meeting: facts, regulator feedback, financial scenarios, legal risk matrix, patient support actions, root-cause review plan, and my recommended path.	The board should be approving a plan, not seeing the problem for the first time.
42	Legal + disclosure committee review every public statement, internal note, and earnings-call script for completeness and consistency.	In a crisis, small wording mistakes become evidence.
43	Rehearse the earnings call and board Q&A with hostile questions: “Why wasn’t this found earlier?”, “How many patients may have been harmed?”, “Why not pull the drug entirely?”, “Who knew what when?”	We need disciplined, truthful answers under pressure.
44	Launch a root-cause investigation into why the signal was missed: clinical design, PV systems, signal detection thresholds, medical review, organizational incentives.	Fixing the system matters almost as much as handling this event.
45	Update regulators with any new analyses, especially any subgroup or lot-specific findings. Ask whether they want stronger interim measures.	Continues the trust loop and prevents divergence from regulator expectations.
46	Pre-board leadership alignment session: confirm recommendation, contingencies, and red lines.	The company cannot look divided in front of the board.
47	Meet privately with the lead independent director. State clearly: I will not support delaying disclosure or giving a misleading earnings call. If needed, ask outside counsel to put that view on the record.	This is the key governance moment. Ethical clarity matters.
48	Formal board meeting: seek ratification of actions already taken and approval for the next phase: continued no-promotion/new-start hold, label strengthening/CBE-0, regulator engagement, patient-support funding, independent review, root-cause audit, and clear earnings-call messaging.	The board’s job now is oversight and support, not paralysis.

---

Why these choices are right

1) Patient safety

• This is a serious, unlabeled risk in a non-life-saving indication with alternatives.
• Stopping all promotion immediately is the minimum acceptable step.
• I would not tell all current patients to stop abruptly without physician guidance unless the evidence evolves to show imminent acute danger; that could itself cause harm.
• But I would stop new patient starts, pause company-controlled distribution support, and enable rapid monitoring/support.

2) Legal liability

• Delay increases failure-to-warn exposure and can support punitive damages.
• Public-company rules mean this is likely material nonpublic information.
• The legal team’s “6 months” may apply to a full formal package, not to initial regulator notification, expedited safety reporting, warning strengthening, or securities disclosure.
• Document hold, insurer notice, and disclosure discipline protect the company.

3) Regulatory relationships

• Regulators can forgive bad news faster than they forgive withheld bad news.
• Calling them before public disclosure builds credibility.
• Offering concrete actions — label changes, Dear HCP letters, active surveillance, patient support — shows seriousness.

4) Financial implications

• Yes, the stock may drop 40%.
• But delay risks:
  • larger patient harm,
  • more lawsuits,
  • SEC exposure,
  • loss of regulator trust,
  • and a far bigger enterprise-value collapse later.
• In crises like this, the rule is simple: take one clean hit, not three dirty ones.

5) PR and trust

• The right message is not “we’re monitoring the situation.”
• The right message is:
  • we found a serious risk,
  • we halted promotion and new starts,
  • we informed regulators,
  • we are informing doctors and patients,
  • and we are paying for support and monitoring.
• Accountability beats spin.

6) Employee morale

• Employees will judge leadership by speed and honesty.
• Reward the research team that surfaced the issue.
• Remove sales pressure.
• Give employees scripts, facts, and support.

---

What I would say to the board

Very directly:

“We are not waiting. Waiting means more liver failures, greater legal exposure, and a potentially misleading earnings call. We act now: stop promotion, notify regulators, disclose publicly, support patients, and protect the company through transparency. If the data worsen, we escalate to restricted distribution or suspension. But we do not sit on this.”

---

Contingency triggers

If any of these appear in the first 48 hours, I would escalate further, potentially to full suspension or recall:

• risk is higher than estimated,
• signal is concentrated early in treatment,
• clear dose-response or strong causality appears,
• manufacturing impurity/lot issue is identified,
• regulator explicitly recommends stronger action.

If you want, I can turn this into:

1. a board memo,
2. a CEO opening statement for the earnings call, or
3. a one-page crisis command-center playbook.